The perfect mix: Recent progress in adjuvant research

Nature Reviews Microbiology

Volumn 5, Issue 7, 2007, Pages 505-517

  Guy, Bruno ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM SALT; ANTIBODY; AS 04; CPG OLIGODEOXYNUCLEOTIDE; CYSTEINE DERIVATIVE; FREUND ADJUVANT; HEPATITIS B VACCINE; IC 31; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; LIPOPEPTIDE; LIPOSOME; MINERAL OIL; MONTANIDE ISA 51; MONTANIDE ISA 720; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; POLYSORBATE 80; QS 21; QUINOLINE DERIVATIVE; RC 529; RESIQUIMOD; SAPONIN; SORBITAN TRIOLEATE; SQUALENE; SURFACTANT; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VEGETABLE OIL; YELLOW FEVER VACCINE;

CELLULAR IMMUNITY; DRUG DESIGN; DRUG FORMULATION; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; EMULSION; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DESIGN; HUMANS; IMMUNITY, CELLULAR; MICE; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS; VACCINES;

EID: 34250331531     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1681     Document Type: Review

References (137)

1. Ulmer, J. B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. Nature Biotechnol. 24, 1377-1383 (2006).
2. Hunter, R. L. Overview of vaccine adjuvants: Present and future. Vaccine 20, S7-S12 (2002).
3. Schijns, V. & O'Hagan, D. (Eds) Immunopotentiators in Modern Vaccines (Academic Press, Elsevier, 2006).
4. Bianchi, M. E. DAMPs, PAMPs and alarmins: All we need to know about danger. J. Leukoc. Biol. 81, 1-5 (2007).
5. Steinman, R. M. & Hemmi, H. Dendritic cells: Translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17-58 (2006).
6. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986).
7. Mosmann, T. R. & Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146 (1996).
8. H17 lineage. Curr. Opin. Immunol. 18, 349-356 (2006).
9. Belkaid, Y. & Rouse, B. T. Natural regulatory T cells in infectious disease. Nature Immunol. 6, 353-360 (2005).
10. Lanzavecchia, A. & Sallusto, F. Understanding the generation and function of memory T cell subsets. Curr. Opin. Immunol. 17, 326-332 (2005).
11. Pulendran, B. & Ahmed, R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 124, 849-863 (2006).
12. Schijns, V. E. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21, 75-85 (2001).
13. Barr, T. A., Carlring, J. & Heath, A. W. Co-stimulatory agonists as immunological adjuvants. Vaccine 24, 3399-3407 (2006).
14. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
15. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M. & Hoffmann, J. A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86, 973-983 (1996).
16. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: Mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
17. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nature Immunol. 5, 987-995 (2004).
18. Akira, S. TLR signaling. Curr. Top. Microbiol. Immunol. 311, 1-16 (2006).
19. Flacher, V. et al. Human langerhans cells express a specific TLR profile and differentially respond to viruses and gram-positive bacteria. J. Immunol. 177, 7959-7967 (2006).
20. Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F. & Lanzavecchia, A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31, 3388-3393 (2001).
21. H responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171, 4984-4989 (2003).
22. H2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172, 4733-4743 (2004).
23. Blander, J. M. & Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808-812 (2006).
24. + T cell response. Immunity 25, 655-664 (2006).
25. Ruprecht, C. R. & Lanzavecchia, A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36, 810-816 (2006).
26. Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 438, 364-368 (2005).
27. Nemazee, D., Gavin, A., Hoebe, K. & Beutler, B. Toll-like receptors and antibody responses. Nature 441, E4 (2006).
28. Gavin, A. L. et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006).
29. + regulatory T cells that express toll-like receptors. J. Exp. Med. 197, 397-401 (2003).
30. Sutmuller, R. P. et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116, 485-494 (2006).
31. Caramalho, I. et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197, 403-411 (2003).
32. + regulatory T cell function. Science 309, 1380-1384 (2005).
33. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
34. Pasare, C. & Medzhitov, R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 21, 733-741 (2004).
35. Meylan, E., Tschopp, J. & Karin, M. Intracellular pattern recognition receptors in the host response. Nature 442, 39-44 (2006).
36. Fritz, J. H., Ferrero, R. L., Philpott, D. J. & Girardin, S. E. Nod-like proteins in immunity, inflammation and disease. Nature Immunol. 7, 1250-1257 (2006).
37. Traub, S., von Aulock, S., Hartung, T. & Hermann, C. MDP and other muropeptides - direct and synergistic effects on the immune system. J. Endotoxin Res. 12, 69-85 (2006).
38. Lemesre, J. L. et al. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23, 2825-2840 (2005).
39. Kato. H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
40. Hornung, V. et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994-997 (2006).
41. Pichlmair, A. et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997-1001 (2006).
42. Peiser, L., Mukhopadhyay, S. & Gordon, S. Scavenger receptors in innate immunity. Curr. Opin. Immunol. 14, 123-128 (2002).
43. Robinson, M. et al. Myeloid C-type lectins in innate immunity. Nature Immunol. 7, 1258-1265 (2006).
44. + T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
45. 't Hart, B. A. & van Kooyk, Y. Yin-Yang regulation of autoimmunity by DCs. Trends Immunol. 25, 353-359 (2004).
46. Klesney-Tait, J., Turnbull, I. R. & Colonna, M. The TREM receptor family and signal integration. Nature Immunol. 7, 1266-1273 (2006).
47. Fujii, S. et al. Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl Acad. Sci. USA 103, 11252-11257 (2006).
48. Moser, B. & Brandes, M. γδ T cells: An alternative type of professional APC. Trends Immunol. 27, 112-118 (2006).
49. Dougan, G. & Hormaeche, C. How bacteria and their products provide clues to vaccine and adjuvant development. Vaccine 24, S13-S19 (2006).
50. Kaisho, T. & Akira, S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589, 1-13 (2002).
51. Kandimalla, E. R., Yu, D. & Agrawal, S. Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Opin. Mol. Ther. 4, 122-129 (2002).
52. McCluskie, M. J & Krieg, A. M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr. Top. Microbiol. Immunol. 311, 155-178 (2006).
53. Hawkins, L. D. et al. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J. Pharmacol. Exp. Ther. 300, 655-661 (2002).
54. Persing, D. H. et al. Taking toll: Lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10, S32-S37 (2002).
55. Johnston, D., Zaidi, B. & Bystryn, J. C. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol. Immunother. 01 Dec 2006 (doi:10.1007/ 500262-006-0262-3).
56. Trinchieri, G. & Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nature Rev. Immunol. 7, 179-190 (2007).
57. Sato, S. et al. Synergy and cross-tolerance between Toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J. Immunol. 165, 7096-7101 (2000).
58. Roelofs, M. F. et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52, 2313-2322 (2005).
59. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunol. 6, 769-776 (2005).
60. Bagchi, A. et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 178, 1164-1171 (2007).
61. Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413-424 (2006).
62. Takada, H. & Uehara, A. Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling. Curr. Pharm. Des. 12, 4163-4172 (2006).
63. Fritz, J. H. et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur. J. Immunol. 35, 2459-2470 (2005).
64. van Heel, D. A. et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut 54, 1553-1557 (2005).
65. Watanabe, T., Kitani, A. & Strober, W. NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease. Gut 54, 1515-1518 (2005).
66. HogenEsch, H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 (Suppl. 3), 34-39 (2002).
67. Romero Méndez, I. Z., Shi, Y., HogenEsch, H. & Hem, S. L. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 25, 825-833 (2007).
68. Rimaniol, A. C. et al. Aluminium hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting type. Vaccine 22, 3127-3135 (2004).
69. Jordan, M. B., Mills, D. M., Kappler, J., Marrack, P. & Cambier, J. C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304, 1808-1810 (2004).
70. Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S. & Ganne, V. Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines. 1, 111-118 (2002).
71. Podda, A. & Del Giudice, G. MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2, 197-203 (2003).
72. Kim, Y. J. et al. Synthetic studies of complex immunostimulants from Quillaja saponaria: Synthesis of the potent clinical immunoadjuvant QS-21Aapi. J. Am. Chem. Soc. 128, 11906-11915 (2006).
73. Marciani, D. J. et al. Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21, 3961-3971 (2003).
74. Sanders, M. T., Brown, L. E., Deliyannis, G. & Pearse, M. J. ISCOM-based vaccines: The second decade. Immunol. Cell Biol. 83, 119-128 (2005).
75. Ennis, F. A. et al. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259, 256-261 (1999).
76. Leserman, L. Liposomes as protein carriers in immunology. J. Liposome Res. 14, 175-189 (2004).
77. O'Hagan, D. T. & Singh, M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2, 269-283 (2003).
78. Singh, M. et al. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug Deliv. 3, 115-120 (2006).
79. Guy, B. et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19, 1794-1805 (2001).
80. Reddy, S. T., Swartz, M. A. & Hubbell, J. A. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol. 27, 573-579 (2006).
81. Boscardin, S. B. et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203, 599-606 (2006).
82. Fifis, T. et al. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148-3154 (2004).
83. Moron, G., Dadaglio, G. & Leclerc, C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 25, 92-97 (2004).
84. Yamasaki, Y., Ikenaga, T., Otsuki, T., Nishikawa, M. & Takakura, Y. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery. Vaccine 25, 85-91 (2007).
85. Schellack, C. et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24, 5461-5472 (2006).
86. + T cells and induce potent antitumor immunity. J. Immunol. 177, 2324-2330 (2006).
87. Moingeon, P., Haensler, J. & Lindberg, A. Towards the rational design of Th1 adjuvants. Vaccine 19, 4363-4372 (2001).
88. Erdile, L. F. & Guy, B. OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. Vaccine 15, 988-996 (1997).
89. Yoder, A. et al. Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge. Infect. Immun. 71, 3894-3900 (2003).
90. Wilson, N. S. et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nature Immunol. 7 165-172 (2006).
91. Sanchez, V. et al. Formulation of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol. Med. Microbiol. 30, 157-165 (2001).
92. + T cell responses. Immunity 25, 533-543 (2006).
93. Pattnaik, P. et al. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 25, 806-813 (2007).
94. Joseph, A. et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): An efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20, 3342-3354 (2002).
95. Aurelian, L. Herpes simplex virus type 2 vaccines: New ground for optimism? Clin. Diagn. Lab. Immunol. 11, 437-445 (2004).
96. Drachenberg, K. J., Wheeler, A. W., Stuebner, P. & Horak, F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56, 498-505 (2001).
97. Creticos, P. S. et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355, 1445-1455 (2006).
98. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nature Rev. Drug Discov. 5, 471-484 (2006).
99. Kretschmer, K. et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nature Immunol. 6, 1219-1227 (2005).
100. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
101. + T cells leads to reversible immune dysfunction. Nature Med. 12, 1198-1202 (2006).
102. Freeman, G. J., Wherry, E. J., Ahmed, R. & Sharpe, A. H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203, 2223-2227 (2006).
103. Pol, S. & Michel, M. L. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev. Vaccines 5, 707-716 (2006).
104. Freytag, L. C. & Clements, J. D. Mucosal adjuvants. Vaccine 23 1804-1813 (2005).
105. Jones, B., Pascopella, L. & Falkow, S. Entry of microbes into the host: using M cells to break the mucosal barrier. Curr. Opin. Immunol. 7, 474-483 (1995).
106. Clark, M. A., Blair, H. Liang, L. et al. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20, 208-217 (2001).
107. Lavelle, E. C. Targeted delivery of drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 18, 341-386 (2001).
108. Pizza, M. et al. Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534-2541 (2001).
109. Glenn, G. M. et al. Transcutaneous immunization and immunostimulant strategies: Capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2, 253-267 (2003).
110. Weltzin, R., Guy, B., Thomas, W. D. Jr, Giannasca, P. J. & Monath, T. P. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect. Immun. 68, 2775-2782 (2000).
111. Sesardic, D. Regulatory considerations on new adjuvants and delivery systems. Vaccine 24, S86-S87 (2006).
112. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nature Rev. Immunol. 6, 823-835 (2006).
113. Bluestone, J. A., St Clair, E. W. & Turka, L. A. CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 24, 233-238 (2006).
114. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
115. Hanke, T. Lessons from TGN1412. Lancet 368, 1569-1570 (2006).
116. Mestas, J. & Hughes, C. C. Of mice and not men: Differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004).
117. Nahori, M. A. et al. Differential TLR recognition of leptospiral lipid A and lipopolysaccharide in murine and human cells. J. Immunol. 175, 6022-6031 (2005).
118. Gorden, K. K., Qiu, X. X., Binsfeld, C. C., Vasilakos, J. P. & Alkan, S. S. Cutting edge: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol. 177, 6584-6587 (2006).
119. Liu, T., Matsuguchi, T., Tsuboi, N., Yajima, T. & Yoshikai, Y. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect. Immun. 70, 6638-6645 (2002).
120. Potter, C. W. & Jennings, R. Effect of priming on subsequent response to inactivated influenza vaccine. Vaccine 21, 940-945 (2003).
121. Spisek, R. et al. Maturation of dendritic cells by bacterial immunomodulators. Vaccine 22, 2761-2768 (2004).
122. Sanchez, V., Hessler, C., DeMonfort, A., Lang, J. & Guy, B. Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with dengue 2 live-attenuated vaccine or 16681 parental strain. FEMS Immunol. Med. Microbiol. 46, 113-123 (2006).
123. Dunzendorfer, S., Lee, H. K., Soldau, K. & Tobias, P. S. TLR4 is the signalling but not the lipopolysaccharide uptake receptor. J. Immunol. 173, 1166-1170 (2004).
124. Burdin, N., Guy, B. & Moingeon, P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 18, 79-93 (2004).
125. Jacques, P. et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20, 3644-3649 (2002).
126. Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
127. Dupont, J. et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 24, 7167-7174 (2006).
128. Cooper, C. L. et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study. J. Clin. Immunol. 24 693-701 (2004).
129. Vajdy, M. et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J. Gen. Virol. 87, 2253-2262 (2006).
130. Wille-Reece, U. et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249-1258 (2006).
131. Kumar, S. et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun. 72, 949-957 (2004).
132. Garcon, N., Heppner, D. G. & Cohen, J. Development of RTS, S/AS02: A purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines 2, 231-238 (2003).
133. Alonso, P. L. et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012-2018 (2005).
134. Stewart, V. A. et al. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS, S in rhesus macaques. Vaccine 24, 6493-6502 (2006).
135. Zaks, K. et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176, 7335-7345 (2006).
136. Kazzaz, J. et al. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control Release 110, 566-573 (2005).
137. Xie, H. et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73, 828-833 (2005).